Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
NCT06719583 · View on ClinicalTrials.gov ↗
Study Summary
BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.
Conditions Studied
Study Locations (12)
Illinois
- Rush University — Chicago
- University of Chicago — Chicago
Louisiana
- Ochsner Clinic Foundation — New Orleans
- Louisiana State University Health Sciences Center Shreveport — Shreveport
Maryland
- University of Maryland — Baltimore
- Kaiser Permanente Midatlantic States — Rockville
Alabama
- University of Alabama at Birmingham — Birmingham
Florida
- University of Florida — Gainesville
Missouri
- Washington University in St. Louis — St Louis
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
South Carolina
- Medical University of South Carolina — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06719583
The ClinicalTrials.gov registry entry for NCT06719583 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06719583 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Illinois, Louisiana, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06719583 about?
NCT06719583 is a clinical study titled "Black and African Americans Connections to Parkinson's Disease (BLAAC PD)". BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to tra...
What is the current status of trial NCT06719583?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2020-11-16. Estimated completion is 2027-12-31.
What conditions does trial NCT06719583 study?
This clinical trial studies the following conditions: Parkinson Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06719583?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06719583 being conducted?
This trial has 12 study locations across Alabama, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.